Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orphan Drugs Compose Majority Of Novel US Approvals For First Time Ever In 2018

Executive Summary

Orphan drugs and priority reviews achieved historic highs in CDER's 2018 novel approval class, but share of products with breakthrough therapies took a slide. 
Advertisement

Related Content

2018 Saw Record Launches, But No Big Splash
Rare Disease Roundtable: How Rare Is Too Rare?
Gottlieb Touts US FDA's Organizational Structure For Advancing Policies During His Tenure
Gottlieb's Short Tenure Will Be Felt Long After He Leaves US FDA
Gottlieb's Short Tenure Will Be Felt Long After He Leaves US FDA
Keeping Track: Tpoxx Wins Green Light For Smallpox, Submissions Galore, And A Broader Approval For Xtandi
Breakthrough, Priority Review Designations Could Set High-Water Marks In 2018
Gottlieb: Epidiolex Approval Covers One Specific Cannabidiol Medication, Not Marijuana
US FDA Sets Records With Breakthrough Therapy, Priority Review Designations In 2017
CDER's 2017 New Drug Class Maintains Steady Innovative Composition With Recent Years

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124491

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel